See more : Atlas Pearls Limited (ATP.AX) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- CEZ, a. s. (CEZYY) Income Statement Analysis – Financial Results
- Scienjoy Holding Corporation (SJOYW) Income Statement Analysis – Financial Results
- Pantech Group Holdings Berhad (5125.KL) Income Statement Analysis – Financial Results
- Aeffe S.p.A. (AEF.MI) Income Statement Analysis – Financial Results
- Aarti Pharmalabs Limited (AARTIPHARM.NS) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
| Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
| Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
| Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
| Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
| Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
| Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
| EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
| EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
| Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
| Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
| Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
| Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
| Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
| Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
| Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
| Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
| EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
| Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
Medable Secures Another $78 Million Funding to Fuel Digital Innovation for Patient-Centered Drug Development
Thermo Fisher to buy PPD, in a cash deal valued at $17.4 billion including debt
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
PPD Stock: 12.1% Increase Explanation
PPD Announces First Quarter 2021 Earnings Conference Call
PPD Announces First Quarter 2021 Earnings Conference Call
PPD Announces First Quarter 2021 Earnings Conference Call
PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data
PPD and Clinical Ink Collaborate on Innovative Process for Lupus Assessment and Near Real-Time Access to Endpoint Data
PPD Named a Leader in Digital Clinical Trial Solutions by ISG
Source: https://incomestatements.info
Category: Stock Reports